Natural Killer Cell Activation Compositions for Timed Transgene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CAR T-cell therapies face challenges with toxicity issues such as cytokine release syndrome, tumor lysis syndrome, B-cell aplasia, and off-target toxicities, while existing regulatory strategies like kill switches and transient CAR expression compromise the surveillance benefit of CAR technology.
Innovation Solution
Utilizing RNA Destabilizing Elements (RDEs) to control transgene expression in CAR-expressing immune cells, combined with Notch receptor signaling inhibitors, to regulate activation and proliferation, and incorporating metabolic state-dependent expression control to optimize therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If kill switch technology is used to control CAR T-cell toxicity, then safety against toxicity is improved, but long-term surveillance benefit is compromised
Solution Approach 1:
The patent employs dynamic control of CAR T-cell activity through transient expression of CAR transgenes. The CAR expression is activated only when needed (upon detection of tumor antigens) and automatically turns off after a predetermined time period, allowing the system to adapt its surveillance and safety properties dynamically rather than being permanently fixed
Solution Approach 2:
The CAR transgene expression is made periodic rather than continuous, activating only during specific time windows when tumor presence is detected. This periodic activation pattern allows the immune system to provide surveillance benefits when needed while automatically reducing toxicity risks when the tumor is eliminated or the window expires
2Object-affected harmful factors
If transient CAR expression is used to control toxicity, then safety is improved, but surveillance benefit is compromised
Solution Approach 1:
The patent incorporates predetermined time limits and activation conditions before full CAR activity begins. The system is pre-programmed with temporal constraints that prevent unlimited persistence of CAR expression, thereby proactively limiting toxicity potential before it can cause harm while still allowing adequate surveillance during the active period
3Productivity
If CAR T-cells are used to treat cancer, then cancer clearance is improved, but off-target toxicities occur
Solution Approach 1:
The patent enhances the specificity of CAR T-cell action by controlling CAR expression in a localized temporal manner. The CAR transgene is activated only in the presence of specific tumor antigens and only for limited durations, creating a localized window of high activity that maximizes cancer clearance while minimizing exposure to normal tissues and preventing off-target effects
4Productivity
If Notch receptor signaling is inhibited to enhance T-cell activation, then proliferation is improved, but cellular inhibition is reduced
Solution Approach 1:
The patent introduces Notch receptor signaling as an intermediary regulatory mechanism that mediates between CAR activation and full T-cell proliferation. By selectively inhibiting Notch signaling only during specific temporal windows after CAR activation, the system allows controlled proliferation enhancement while preventing excessive cellular inhibition that would counteract the therapeutic effect
Data Source
AI summary
Methods and compositions for controlling transgene expression in Natural Killer Cells are disclosed. Also, disclosed are RDEs which can be used to optimize expression of transgenes in NK cells following activation pf the NK cell through a receptor, e.g., CARs or T-cell receptors. CARs and transgene payloads can also be engineered into NK cells so that the transgene payload is expressed and delivered at desired times from the NK cell. Such CAR NK cells with transgene payloads can be combined with the administration of other molecules, e.g., other therapeutics such as anticancer therapies.